ReviewLiver cancer2025
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).
Abstract readReview
In one paragraph
Review in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- IL-6/STAT3 signaling pathway-mediated apoptosis induced by medical ozone water in liver cancer: A mechanistic study.Biomedical reports · 2026Article
- Hepatocellular Carcinoma Over Three Decades: from Screening Evolution to Integrated Therapeutic Strategies.Journal of cancer prevention · 2026Review
- Anti-Hepatocarcinoma Activity and Mechanism of Isosendanin and Its Novel Structural Analogues Isolated from the Bark ofAntioxidants (Basel, Switzerland) · 2026Article
- Effect of laparoscopic anatomical hepatectomy for hepatocellular carcinoma based on individualized three-dimensional reconstruction model of portal vein region.World journal of surgical oncology · 2026Article
- Pioneering efficient deep learning architectures for enhanced hepatocellular carcinoma prediction and clinical translation.World journal of gastrointestinal oncology · 2026Article
- Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside.Frontiers in immunology · 2026Review
- Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study.Frontiers in oncology · 2026Article
- Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).Journal of clinical and translational hepatology · 2025Article
- Development of a predictive nomogram for in-hospital death risk in multimorbid patients with hepatocellular carcinoma undergoing Palliative Locoregional Therapy.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
71 authors.
Yu YangDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Juxian SunDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Minshan ChenDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chaoliu DaiDepartment of Hepatobiliary and Splenic Surgery, Shengjing Hospital Affiliated to China Medical University, Shenyang, China.
Tianfu WenDepartment of Liver Surgery & Liver Transplantation Centre, West China Hospital of Sichuan University, Chengdu, China.
Jinglin XiaLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Mingang YingDepartment of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, China.
Zhiwei ZhangDepartment of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xuewen ZhangDepartment of Hepatobiliary and Pancreas Surgery, The Second Hospital of Jilin University, Changchun, China.
Chihua FangDepartment of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Feng ShenDepartment of Hepatic Surgery IV, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Ping AnDepartment of Infectious Diseases, The Sixth People's Hospital of Shenyang, Shenyang, China.
Qingxian CaiNational Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China.
Jingyu CaoDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Zhen ZengComprehensive Liver Cancer Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Gang ChenDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Juan ChenDepartment of Radiology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Ping ChenDepartment of Infectious Diseases, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Yongshun ChenDepartment of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Yunfeng ShanDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shuangsuo DangDepartment of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Wei-Xing GuoDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Jiefeng HeDepartment of Hepatobiliary Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, China.
Heping HuDepartment of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Bin HuangDepartment of Radiology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Weidong JiaDepartment of General Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
Kexiang JiangDepartment of Hepatobiliary Surgery, Zhuji People's Hospital of Zhejiang Province, Zhuji, China.
Yan JinDepartment of Hepatobiliary and Pancreatic Surgery, First People's Hospital of Yunnan Province, Affiliated Hospital of KMUST, Kumming, China.
Yongdong JinDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yun JinDepartment of Hepatobiliary and Pancreatic Surgery, First People's Hospital of Yunnan Province, Affiliated Hospital of KMUST, Kumming, China.
Gong LiDepartment of Radiation Oncology, Beijing Tsinghua Changgung Hospital, Beijing, China.
Yun LiangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Enyu LiuDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, China.
Hao LiuCancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Wei PengDepartment of Liver Surgery & Liver Transplantation Centre, West China Hospital of Sichuan University, Chengdu, China.
Zhenwei PengCancer Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zhiyi PengDepartment of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yeben QianDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Wanhua RenDepartment of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Jie ShiDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yusheng SongDepartment of Interventional Radiology, Ganzhou People's Hospital, Ganzhou, China.
Min TaoDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jun TieNational Clinical Research Center for Digestive Diseases, State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Military Medical University, Xi'an, China.
Xueying WanDepartment of Chinese Traditional Medicine, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Bin WangDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Jin WangDepartment of Oncology, MianYang Central Hospital, MianYang, China.
Kai WangHepato-Biliary-Pancreatic Surgery Division, Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Kang WangDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Xin WangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wenjing WeiDepartment of General Surgery, Taiyuan People's Hospital, Taiyuan, China.
Fei-Xiang WuDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Bangde XiangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
Lin XieDepartment of Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Jianming XuDepartment of Gastrointestinal Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Mao-Lin YanDepartment of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, China.
Yufu YeDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jinbo YueDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xiaoxun ZhangDepartment of Liver Surgery & Liver Transplantation Centre, West China Hospital of Sichuan University, Chengdu, China.
Yu ZhangHepatobiliary and Pancreatic Surgery Department, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Aibin ZhangDepartment of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
Haitao ZhaoDepartment of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weifeng ZhaoDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xin ZhengDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hongkun ZhouDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing College, Jiaxing, China.
Huabang ZhouDepartment of Gastroenterology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Jun ZhouDepartment of Medical Oncology, Beijing Cancer Hospital, Beijing, China.
Xinmin ZhouDepartment of Gastroenterology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Shu-Qun ChengDepartment of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Qiu LiDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Chinese Association of Liver Cancer and Chinese Medical Doctor Association
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Most HCC patients have the complications of chronic liver disease and need overall consideration and whole-course management, including diagnosis, treatment, and follow-up. To develop a reasonable, long-term, and complete management plan, multiple factors need to be considered, including the patient's general condition, basic liver diseases, tumor stage, tumor biological characteristics, treatment requirements, and economic cost. Summary: To better guide the whole-course management of HCC patients, the Chinese Association of Liver Cancer and the Chinese Medical Doctor Association has gathered multidisciplinary experts and scholars in relevant fields to formulate the "Chinese Expert Consensus on The Whole-Course Management of Hepatocellular Carcinoma (2023)." Key Messages: This expert consensus, based on the current clinical evidence and experience, proposes surgical and nonsurgical HCC management pathways and involves 18 recommendations, including perioperative treatment, systematic treatment combined with local treatment, conversion treatment, special population management, symptomatic support treatment, and follow-up management.
Indexed as
Hepatocellular carcinomaSurgerySurveillanceSystemic chemotherapyTreatment
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.